Download PDF
Neuropediatrics 2007; 38(1): 10-17
DOI: 10.1055/s-2007-981686
Original Article

© Georg Thieme Verlag KG Stuttgart · New York

Clinical Presentation and Course of Childhood Guillain-Barré Syndrome: A Prospective Multicentre Study

R. Korinthenberg 1 , J. Schessl 1 , J. Kirschner 1
  • 1Division of Neuropaediatrics and Muscular Disorders, Department of Paediatrics and Adolescent Medicine, University Hospital, Freiburg, Germany
Further Information

Publication History

received 4.7.2006

accepted 24.4.2007

Publication Date:
02 July 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Presenting symptoms, clinical course and paraclinical findings in childhood Guillain-Barré syndrome (GBS) have rarely been investigated prospectively. We performed a multicentre study in GBS diagnosed according to international criteria. Clinical findings were recorded using an ordinal GBS score and additional scores for arm, cranial nerve and vegetative function, and pain. Electrophysiological and CSF investigations followed individual procedures in the local hospitals. Ninety-five children with a median age of 6.2 years were registered over 40 months (53 boys, 42 girls). 70 had suffered an infection and 8 had been vaccinated during the previous 6 weeks. The first symptom was usually a disturbance of gait or neuropathic pain. The symptoms progressed for a median of 7 days. At the height of the disease, 60% of patients were unable to walk and 24% could not use their arms. 46% showed cranial nerve involvement, and 51% autonomous dysfunction. 13% required artificial ventilation. 79% complained of neuropathic pain, half of them to a severe degree. Electrophysiological examination showed demyelination in 74%, and 26% of these presented with very low amplitude compound action potentials. Purely axonal changes were found in 11%. All but eight were treated with i.v. immunoglobulin. Improvement began on day 13 after the first symptom (median). Ability to walk unaided returned after 27 days. In the children observed over the long-term, it took 118 days for them to be free of symptoms. Transient deterioration after immunoglobulin treatment occurred in seven patients, two suffered relapsing GBS, and three developed CIDP. At the end of the observation period (288 days), 75% of patients were free of symptoms. 21% suffered residual symptoms having no effect on daily functioning. The more severely disabled 4% either suffered from CIDP or concurrent myelitis. With this prospective study, the results of earlier retrospective investigations are confirmed. Besides pareses and respiratory compromise, severe neuropathic pain frequently is a therapeutic challenge during the acute phase of the disease. The long-term prognosis is good for most children. However, a change to CIDP and concurrent myelitis can give rise to a worse prognosis.

Key words

Guillain Barré syndrome - immunoglobulins - childhood - disability - nerve conduction study

References

  • 1 Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM. Intravenous immunoglobulin as therapy for pediatric Guillain- Barré syndrome.  J Child Neurol. 1997;  12 376-380
    PubMedGoogle Scholar
  • 2 Asbury AK. New concepts of Guillain-Barré syndrome.  J Child Neurol. 2000;  15 183-191
    CrossrefPubMedGoogle Scholar
  • 3 Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome.  Ann Neurol. 1990;  27 S21-S24
    CrossrefPubMedGoogle Scholar
  • 4 Bradshaw DY, Jones HR. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis.  Muscle Nerve. 1992;  15 500-506
    PubMedGoogle Scholar
  • 5 Delanoe C, Sebire G, Landrieu P, Huault G, Metral S. Acute inflammatory demyelinating polyradiculoneuropathy in children: Clinical and electrodiagnostic studies.  Ann Neurol. 1998;  44 350-356
    CrossrefPubMedGoogle Scholar
  • 6 Gibbels E, Giebisch U. Natural course of acute and chronic monophasic inflammatory demyelinating polyneuropathies (IDP). A retrospective analysis of 266 cases.  Acta Neurol Scand. 1992;  85 282-291
    PubMedGoogle Scholar
  • 7 Gürses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome.  Scand J Infect Dis. 1995;  27 241-243
    PubMedGoogle Scholar
  • 8 Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV. et al . Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.  Ann Neurol. 1998;  44 780-788
    CrossrefPubMedGoogle Scholar
  • 9 Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J. et al . Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.  Neurology. 2001;  56 758-765
    CrossrefPubMedGoogle Scholar
  • 10 Hart DE, Rojas LA, Rosário JA, Recalde H, Román GC. Childhood Guillain-Barré syndrome in Paraguay, 1990 to 1991.  Ann Neurol. 1994;  36 859-863
    CrossrefPubMedGoogle Scholar
  • 11 Hartung HP, Kieseier BC, Kiefer R. Progress in Guillain-Barré syndrome.  Curr Opin Neurol. 2001;  14 597-604
    CrossrefPubMedGoogle Scholar
  • 12 Hughes RA, Raphael JC, Swan AV, Doorn PA van. Intravenous immunoglobulin for Guillain-Barré syndrome.  Cochrane Database of Systematic Reviews. 2004;  3
    PubMedGoogle Scholar
  • 13 Hughes RA, Cornblath DR. Guillain-Barré syndrome.  Lancet. 2006;  366 1653-1666
    PubMedGoogle Scholar
  • 14 Hung KL, Wang HS, Liou WY, Mak SC, Chi CS, Shen EY. et al . Guillain-Barré syndrome in children: a cooperative study in Taiwan.  Brain Dev. 1994;  16 204-208
    CrossrefPubMedGoogle Scholar
  • 15 Hung PL, Chang WN, Huang LT, Huang SC, Chang YC, Chang CJ. et al . A clinical and electrophysiologic survey of childhood Guillain-Barré syndrome.  Pediatr Neurol. 2004;  30 86-91
    CrossrefPubMedGoogle Scholar
  • 16 Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin.  Neurology. 1993;  43 872-875
    PubMedGoogle Scholar
  • 17 Jones HR. Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy.  J Child Neurol. 1996;  11 4-12
    PubMedGoogle Scholar
  • 18 Kanra G, Ozon A, Vajsar J, Castagna L. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome.  Eur J Paediatr Neurol. 1997;  1 7-12
    CrossrefPubMedGoogle Scholar
  • 19 Kleyweg RP, Meche FG van der. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.  J Neurol Neurosurg Psychiatry. 1991;  54 957-960
    CrossrefPubMedGoogle Scholar
  • 20 Korinthenberg R, Schulte Mönting J. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study.  Arch Dis Child. 1996;  74 281-287
    CrossrefPubMedGoogle Scholar
  • 21 Korinthenberg R. Chronic inflammatory demyelinating polyradiculoneuropathy in children and their response to treatment.  Neuropediatrics. 1999;  30 190-196
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Korinthenberg R, Schessl J, Kirschner J, Schulte Mönting J. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.  Pediatrics. 2005;  116 8-14
    CrossrefPubMedGoogle Scholar
  • 23 Koul R, Chacko A, Ahmed R, Varghese T, Javed H, Al-Lamki Z. Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras.  J Child Neurol. 2003;  18 767-771
    PubMedGoogle Scholar
  • 24 Martens-Le Bouar H, Korinthenberg R. Polyradiculoneuritis with myelitis: a rare differential diagnosis of Guillain-Barré syndrome.  Neuropediatrics. 2002;  33 93-96
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Mac Khann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. et al . Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis.  Ann Neurol. 1988;  23 347-353
    CrossrefPubMedGoogle Scholar
  • 26 Molinero MR, Varon D, Holden KR, Sladky JT, Molina IB, Cleaves F. Epidemiology of childhood Guillain-Barré syndrome as a cause of acute flaccid paralysis in Honduras: 1989-1999.  J Child Neurol. 2003;  18 741-747
    PubMedGoogle Scholar
  • 27 Nagasawa K, Kuwabara S, Misawa S, Fujii K, Tanabe Y, Yuki N. et al . Electrophysiological subtypes and prognosis of childhood Guillain-Barré syndrome in Japan.  Muscle Nerve. 2006;  33 766-770
    CrossrefPubMedGoogle Scholar
  • 28 Nguyen DK, Agenarioti-Belanger S, Vanasse M. Pain and the Guillain-Barré syndrome in children under 6 years old.  J Pediatr. 1999;  134 773-776
    PubMedGoogle Scholar
  • 29 Odaka M, Yuki N, Hirata K. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome.  J Neurol. 2003;  250 913-916
    PubMedGoogle Scholar
  • 30 Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal.  Ann Neurol. 1999;  46 701-707
    CrossrefPubMedGoogle Scholar
  • 31 Plasma Exchange/Sandoglobulin Gullain-Barré syndrome trial group. . A randomized trial comparing intravenous immune globulins and plasma exchange in Guillain-Barré syndrome.  Lancet. 1997;  349 225-230
    CrossrefPubMedGoogle Scholar
  • 32 Rantala H, Uhari M, Niemelä M. Occurrence, clinical manifestations, and prognosis of Guillain-Barré syndrome.  Arch Dis Child. 1991;  66 706-709
    PubMedGoogle Scholar
  • 33 Rossi LN, Mumenthaler M, Lütschg J, Ludin HP. Guillain-Barré syndrome in children with special reference to the natural history of 38 personal cases.  Neuropädiatrie. 1976;  7 42-51
    PubMedGoogle Scholar
  • 34 Ruts L, Koningsveld R van, Doorn PA van. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations.  Neurology. 2005;  65 138-140
    CrossrefPubMedGoogle Scholar
  • 35 Sakakihara Y, Kamoshita S. Age-associated changes in the symptomatology of Guillain-Barré syndrome in children.  Dev Med Child Neurol. 1991;  33 611-616
    PubMedGoogle Scholar
  • 36 Schessl J, Luther B, Kirschner, Mauff G, Korinthenberg R. Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study.  Eur J Pediat. 2006;  165 605-612
    CrossrefPubMedGoogle Scholar
  • 37 Schessl J, Koga M, Funakoshi K, Kirschner J, Muellges W, Weishaupt A. et al . Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome.  Arch Dis Child. 2007;  92 48-52
    CrossrefPubMedGoogle Scholar
  • 38 Shahar E, Shorer Z, Roifman CM, Levi Y, Brand N, Ravid S. et al . Immune globulins are effective in severe pediatric Guillain-Barré syndrome.  Pediatr Neurol. 1997;  16 32-36
    CrossrefPubMedGoogle Scholar
  • 39 Sladky JT. Guillain-Barré syndrome in children.  J Child Neurol. 2004;  19 191-200
    PubMedGoogle Scholar
  • 40 Vajsar J, Sloane A, Wood E, Murphy EG. Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome.  Arch Pediatr Adolesc Med. 1994;  148 1210-1212
    PubMedGoogle Scholar
  • 41 Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barré syndrome.  J Pediatr. 2003;  142 305-309
    CrossrefPubMedGoogle Scholar
  • 42 Meche FG van der, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.  N Engl J Med. 1992;  326 1123-1129
    PubMedGoogle Scholar
  • 43 Vedeler CA, Wik E, Nyland H. The long-term prognosis of Guillain-Barré syndrome. Evaluation of prognostic factors including plasma exchange.  Acta Neurol Scand. 1997;  95 298-302
    CrossrefPubMedGoogle Scholar
  • 44 Visser LH, Schmitz PI, Meulstee J, Doorn PA van, Meché FG van der. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group.  Neurology. 1999;  53 598-604
    PubMedGoogle Scholar

Correspondence

Prof. Dr. R. Korinthenberg

Division of Neuropaediatrics and Muscular Disorders

Department of Paediatrics and Adolescent Medicine

University Hospital Freiburg

Mathildenstr. 1

79106 Freiburg

Germany

Phone: +49/761/270 43 15

Fax: +49/761/270 44 75

Email: rudolf.korinthenberg@uniklinik-freiburg.de